Articles On Immuron (ASX:IMC)

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Harvard University’s teaching hospital will adopt Echo IQ’s AI-based aortic stenosis detection tool Immuron trots out its Travelan agenda at its AGM Oncosil goes hot and cold with latest distribution deals   Echo IQ (ASX:EIQ) has won the...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

ASX rises as banking and tech sectors lead gains Arcadium Lithium surges on potential acquisition by Rio Tinto Retail groups urge Reserve Bank to cut rates ahead of holiday sales   The ASX200 index rose by 0.7% on Monday though investors...

    ASX edges down in a quiet market Pilbara Minerals falls 5pc as share block sale is reported Westpac sells auto finance unit for up to $1.6 billion   The ASX has lifted slightly on Thursday, up by 0.1%, as traders remain cautious amid...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

Momentum trading involves buying rising stocks and selling falling ones This works best during economic expansion, when market trends are stronger We take a look at three signals momentum traders use Momentum trading is a popular investme...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

IMM files a pre-IND application with US FDA for IMM-529 targeting common pathogen clostridioides difficile Ansell completes 100% acquisition of the assets of US giant Kimberly-Clark Corporation’s personal protective business Actinogen Xana...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Steve Lydeamore’s advice to biotech peers seeking to do business with the US military is to be armed with a high knowledge readiness level (KRL) when it comes to interpreting acronyms such as … KRL. The head of traveller’s diarrhoea fighter...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. The strategy makes a calculated bet that the stock market’s recent winners will remain winners. The Relative Strength Index (RSI) is a popular...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

  Local markets gives up early gains, ekes out 0.1pc advantage IT and Utilities offset by Energy sector losses Small Caps led by RMI and Narryer Metals   We’re slightly higher at match out in Sydney. But big banks became bad banks after l...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. It involves betting that the stock market’s recent winners will remain winners. One of the best known momentum traders in the world is hedge f...

This week’s Bulls N’ Bears top ASX runner is… Macro Metals. Its share price rose more than 166 per cent to join fellow movers and shakers Immuron, Sultan Resources and Dynamic Metals.

Stockhead’s Top 10 at 11, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percenta...

The ASX200 closed up 0.4 per cent. Industrials & IT led the ranks – both up more than a per cent – while energy weighed on the market, losing well over 1.1 per cent.   What drove industrials? The standout was a company, Wiseway Gr...

The ASX 200 lifted modestly by +0.2% on Thursday as gains in Tech and Industrial stocks were offset by losses in Energy.  Local traders brushed out dovish comments from Fed Chair Jerome Powell last night. Appearing before Congress, Powell r...

The ASX200 has been trading up 0.18 per cent to just above 7,745 points – not by the nearly half a per cent tipped before the market opened this morning. The Industrials sector has made the greatest gains, edging up close to a per cent a...

07 Mar 2024 - A snapshot of the stocks on the move, featuring Dotz Nano (ASX:DTZ, OTC:DTZNY), Immuron (ASX:IMC; NASDAQ:IMRN) and Avecho Biotechnology (ASX:AVE).

Immuron jumps 80pc Travelan shown to be effective The trial is now set to to progress to Phase 3 Doctor Care Anywhere announces a new, permanent CEO   Immuron almost doubles on Travelan results Immuron (ASX:IMC) jumped by over 80% this mo...

Australian biopharmaceutical company Immuron (ASX: IMC) has released interim topline results from a US-based clinical trial of lead candidate IMM-124E (Travelan) confirming that a single daily dose can be effective in the prevention of mode...

A little-known ASX healthcare stock is setting the bar sky-high today. In morning trade on Thursday, the All Ordinaries Index (ASX: XAO) is up 0.2%, while shares in this biopharmaceutical company just rocketed 96.9% to 13 cents apiece. Th...

  To register for Friday's webinar click here. Dotz Nano (ASX:DTZ, OTC:DTZNY), a leading developer of innovative climate and industrial nanotechnologies, today announced the completion of a bench-scale demonstration unit for its carbon capt...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Immuron reports record sales for Travelan in January Neurotech extends Phase 1/2 clinical trial for benefit of patients   Immuron’s record sales Immuron (ASX:IMC) has just announced record sales (unaudited) for Travelan for the January pe...

Immuron (ASX:IMC) has announced record sales of its over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract, Travelan.

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

ASX 200 closes higher for a fifth straight day All 11 Sectors make it home for supper Small caps led by Zuleika and Creasy   It’s fair to say the little battler of an Aussie sharemarket’s put in a real decent day’s work. As various part...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Immuron (IMC) announces a 136 per cent increase in FY23 global sales on FY22 sales The sales of its over-the-counter gastrointestinal and digestive health immune supplements Travelan and Protectyn rose from $765,000 in FY22 to $1.80 mill...

Cann Group’s FY23 sales were 2.1 times that of FY22 Immuron’s FY23 sales increased by 136% from the previous year   Cann Group doubles its sales revenue Cannabis house Cann Group (ASX:CAN) rose 8% this morning after releasing its full yea...

The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley   Throughout history,...

By Tim Boreham ASX code: ((DXB)) Share price: 7.0c Shares on issue: 320,748,666* Market cap: $22.5m Chief executive officer: Dr Nina Webster Board: Hugh Alsop (chair), Dr Webster, Dr Sonia Poli, Clinton Snow Financials (March quarter 2023):...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...